Zubsolv FDA Approval History
FDA Approved: Yes (First approved July 3, 2013)
Brand name: Zubsolv
Generic name: buprenorphine and naloxone
Dosage form: Sublingual Tablets
Company: Orexo AB
Treatment for: Opiate Dependence
Zubsolv (buprenorphine and naloxone) is a sublingual partial opioid agonist indicated for the maintenance treatment of opioid dependence.
Development timeline for Zubsolv
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.